The Center for Therapeutic Target Validation (CTTV), an organization dedicated to preserving communication and interaction between academic institutions and the medical community, recently introduced Cambridge, Massachusetts-based pharmaceutical company Biogen as a new member.
Daklinza, a product of pharmaceutical company Bristol-Myers Squibb that has been available as a treatment for chronic hepatitis C virus (HCV) genotype 3, recently received approval from the U.S. Food and Drug Administration (FDA) for additional uses.
Patients living with rheumatoid arthritis, adult ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and adult and pediatric Crohn’s disease may soon have a new option for treatment.
Biosimilars leader Sandoz, an offshoot of pharmaceutical company Novartis, now holds the rights for the development and commercialization of infliximab, a tumor necrosis factor alpha (TNF-alpha) inhibitor used to treat several autoimmune diseases.
A new scholarship is available through global biopharmaceutical firm AbbVie. Students with rheumatological diseases are eligible for the AbbVie Rheumatology Scholarship. Fifteen scholarships worth $15,000 each will be awarded for the 2016-17 school year.
Enrollment has concluded for a Phase III trial of the genetic-based biomarker risk assignment algorithm (BRAA), which will assess the safety and effectiveness of investigational therapy pioglitazone 0.8 mg SR.
A new study, conducted by researchers from Boston University and funded by the National Institutes of Health (NIH), shows that mothers who sleep in the same room -- but not in the same bed -- as their infants are no less likely to breastfeed than those who sleep in the same beds.
A recent study, conducted by the AAFP National Research Network, investigated the reasons black adults in the U.S. die twice as often as Caucasian adults due to asthma, as well as possible treatments for black patients with asthma.
Five innovative research projects focused on thromboembolic diseases have received a financial boost from the European Society of Cardiology's (ESC) Grants for Medical Research Innovation, a program of pharmaceutical company Boehringer Ingelheim.
Last October, the Centers for Disease Control and Prevention (CDC) awarded a multimillion-dollar grant to the Lupus Foundation of America (LFA) to help promote awareness of the autoimmune disease that affects an estimated five million people worldwide.